FLT3 Inhibitor Doubles Overall Survival in Acute Myeloid Leukemia

(MedPage Today) -- Incorporating quizartinib into standard treatment for newly diagnosed acute myeloid leukemia (AML) followed by maintenance therapy with the investigational FLT3 inhibitor improved survival for patients with internal-tandem-duplication...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news